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Abstract
Background and Aims: The prospective, observational Swiss 
Eosinophilic Esophagitis Cohort Study (SEECS) was set up in 
2015 with the following goals in mind: (1) to provide up-to-
date epidemiologic data; (2) to assess the appropriateness of 
care; (3) to evaluate the psychosocial impact; and (4) to foster 
translational research projects. Data capture relies on vali-
dated instruments to assess disease activity and focuses on 
epidemiologic variables and biosamples (esophageal biop-
sies and blood specimens). An annual inclusion of 70 new 
patients with eosinophilic esophagitis (EoE) or proton pump 
inhibitor-responsive esophageal eosinophilia (PPI-REE) is in-
tended. We herein describe the SEECS cohort profile. Meth-
ods: The SEECS includes adult patients (age ≥18 years) with 
EoE or PPI-REE diagnosed according to published criteria. Af-
ter inclusion, the patients are typically seen once a year for a 
clinical and endoscopic/histologic follow-up examination. 
Data are captured using validated questionnaires. Biosam-
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ples from patients with gastroesophageal reflux disease 
(GERD) and controls with a healthy esophagus are collected 
as well. Results: From January 2016 to July 2017, a total of 
111 patients with EoE and 10 patients with PPI-REE were re-
cruited. In addition, esophageal biopsies and blood samples 
from 11 patients with GERD and 20 controls with a healthy 
esophagus were collected. The mean age of the patients 
with EoE and those with PPI-REE was 39.6 ± 12.9 and 44.6 ± 
15.6 years, respectively. A male predominance was found 
among both the patients with EoE (77.5%) and those with 
PPI-REE (70%). Concomitant allergic disorders were found in 
79.3% of the patients with EoE and 90% of the patients with 
PPI-REE. At inclusion, the EoE patients were treated with the 
following therapeutic regimens: no therapy (0.9%), PPI 
(36%), swallowed topical corticosteroids (82.9%), elimina-
tion diets (15.3%), and esophageal dilation (19.8%). Conclu-
sions: The SEECS is the first national cohort study of patients 
with EoE or PPI-REE. The SEECS will provide up-to-date epi-
demiologic data and foster translational research projects.
© 2018 S. Karger AG, Basel
Introduction
Key Points on Eosinophilic Esophagitis
The first consecutive case series of patients with eo-
sinophilic esophagitis (EoE) were published in 1993 and 
1994 by Attwood et al. [1] and Straumann et al. [2] in the 
USA and in Switzerland, respectively. EoE is currently 
defined as “a chronic, immune/antigen-mediated, esoph-
ageal disease, characterized clinically by symptoms relat-
ed to esophageal dysfunction and histologically by eosin-
ophil-predominant inflammation” [3, 4]. EoE patients 
are mostly male, and a high prevalence of allergies against 
inhalable or food allergens is observed [5–7]. Symptoms, 
mostly dysphagia, have typically already been present for 
years before EoE is diagnosed [8]. The disease is observed 
in industrialized countries with increasing frequency. 
The current incidence ranges from 1 to 20 new patients 
per 100,000 inhabitants per year (mean value 7) and the 
prevalence ranges between 13 and 49 cases per 100,000 
inhabitants [4].
In recent years, clinicians and researchers have be-
come aware of the fact that some patients with EoE-typi-
cal clinical, endoscopic, and histologic features respond-
ed to proton pump inhibitors (PPI). Of note, these pa-
tients did not suffer from gastroesophageal reflux disease 
(GERD). Thus, the term “proton pump inhibitor-respon-
sive esophageal eosinophilia” (PPI-REE) was created [4, 
5]. Patients with PPI-REE cannot be discriminated from 
“real” EoE patients based on clinical, genetic, endoscopic, 
and histologic features, which suggests that these patients 
are within the spectrum of EoE and do not represent a 
separate disease entity [9, 10].
The pathogenesis of EoE (and PPI-REE) is still incom-
pletely understood [6]. It is generally accepted that EoE 
results from a complex interplay between genetic, envi-
ronmental, and host immune systemic factors, compa-
rable to inflammatory bowel disease (IBD) [6]. There ex-
ists increasing evidence that EoE is a chronic progressive 
disease that – if eosinophil-predominant inflammation 
remains untreated – can lead to esophageal remodeling 
processes with fibrous tissue deposition and consecutive 
stricture formation [11–15]. The presence of esophageal 
strictures represents the key risk factor for the feared food 
bolus impactions that might necessitate endoscopic dis-
impaction as an emergency procedure [16, 17].
There exist several reasons for treating active EoE: 
first, to reduce EoE-related symptoms and to improve 
EoE-related quality of life [18, 19], and second, in the long 
run, to reduce or prevent esophageal remodeling process-
es that are associated with stricture formation and food 
bolus impaction. The therapy options for treating EoE 
can be summarized as the “3 D’s,” which stands for “drugs, 
diet, and dilation.” For an in-depth review of the therapy 
recommendations regarding the use of elimination diets, 
drug therapy, and esophageal dilation, we kindly refer to 
evidence-based statements and recommendations for 
diagnosis and management in children and adults [4].
Recent Achievements in Standardizing the Assessment 
of Disease Activity in EoE
Disease activity in EoE can be assessed by patient-re-
ported outcomes (PRO) and clinician-reported outcomes 
(ClinRO) [20, 21]. Concerted efforts of EoE researchers 
have led to the development and validation of EoE-spe-
cific instruments for measuring clinical, endoscopic, and 
histologic EoE activity. EoE-specific symptoms are as-
sessed by the Eosinophilic Esophagitis Activity Index 
(EEsAI) PRO instrument or the Dysphagia Symptom 
Questionnaire (DSQ) [22, 23]. The development and val-
idation of the EEsAI PRO instrument followed recom-
mendations from regulatory authorities [24]. EoE-specif-
ic quality of life can be measured using the validated score 
developed by Taft et al. [18]. Endoscopic activity is as-
sessed using the EREFS (Endoscopic Reference Score) 
classification and grading system, which evaluates exu-
dates, rings, edema, furrows, and strictures [25]. Histo-
logic activity has been evaluated by counting the peak eo-
sinophil number per high-power field (400-fold magni-
Cohort Profile: The Swiss Eosinophilic 
Esophagitis Cohort Study
165Inflamm Intest Dis 2017;2:163–170
DOI: 10.1159/000486131
fication). Recently, a histologic score has been published 
that contains 8 distinct items for the assessment of EoE 
activity [26]. In EoE, both PRO and ClinRO measures 
contribute to the assessment of disease activity [21]. As 
such, most clinical trials assess both PRO and ClinRO 
(e.g., histologic and endoscopic) to obtain a global view 
of EoE activity. As yet, there exists no pharmacologic 
treatment specifically for EoE that has been granted ap-
proval from regulatory authorities.
Rationale for the Study
With the first patients described in 1993, EoE is con-
sidered to be a “young” disease with many unknowns. A 
prospective cohort study of EoE and PPI-REE patients is 
best suited to address some of the unmet needs that have 
recently been summarized in the updated 2017 EoE 
guidelines [4]. Topics to be addressed include, among 
others, the following questions: what environmental risk 
factors can be identified as being associated with EoE and 
PPI-REE? Why do antigens that have been present in sta-
ple foods for centuries cause EoE now? Is treatment with 
swallowed topical steroids and PPI more effective than 
monotherapy with swallowed topical steroids? What fac-
tors determine if an EoE patient will rapidly develop a 
stricturing phenotype? What is an optimal histologic cut-
off (peak eosinophils/mm2) to be reached in the long run 
to prevent stricture formation? Are there safety issues 
with patients on PPI (e.g., osteoporosis) or on topical ste-
roids swallowed over a long period of time (e.g., adrenal 
suppression)?
As such, the general goal of the Swiss Eosinophilic 
Esophagitis Cohort Study (SEECS) is to provide the scien-
tific community with a disease-oriented prospective co-
hort of patients suffering from EoE and PPI-REE. The 
SEECS will (1) provide up-to-date epidemiologic data 
(e.g., regarding the clinical course of EoE) that allow in-
vestigating risk factors associated with a favorable or un-
favorable disease course; (2) document medical care given 
to patients in order to assess the appropriateness of care; 
(3) evaluate the psychosocial impact of EoE; and (4) foster 
translational research projects making use of the biobank 
(e.g., evaluation of esophageal barrier dysfunction).
Cohort Description
Pilot Study
To learn more about the incidence and prevalence of EoE in 
Switzerland, our research group conducted population-based 
studies in two indicator regions of Switzerland. The first one was 
conducted in Olten county in the German-speaking part of Swit-
zerland, and the other one in the canton of Vaud in the French-
speaking part of Switzerland [27, 28]. In Olten county, we found 
an EoE prevalence of about 1 in 2,000 inhabitants (in the period of 
2007–2009), and in the canton of Vaud of 1 in 4,000 inhabitants 
(in the year 2013). While in Olten county EoE was diagnosed for 
the first time already in 1989, in the canton of Vaud it was diag-
nosed only in 2003. The EoE incidence rates were similar between 
Olten county (7.4/100,000 in the period between 2007 and 2009) 
and the canton of Vaud (6.3/100,000 in the year 2013). Thus, we 
are anticipating that the EoE prevalence in the French-speaking 
part of Switzerland will be on the rise in the near future, and prob-
ably approach prevalence rates similar to those in the German-
speaking part of Switzerland in due time.
Setting, Location, and Relevant Data
The SEECS datacenter is located at the Institute of Social and 
Preventive Medicine of the University of Lausanne in Switzerland. 
The SEECS datacenter is incorporated into the Swiss IBD Cohort 
Study (SIBDCS), which has been recruiting patients with IBD since 
2006 [29]. The SEECS became part of the SIBDCS as a large nested 
project in 2015. The reasons for initiating the SEECS were the ob-
servation of a rapidly increasing incidence and prevalence of EoE 
and PPI-REE in Switzerland and the realization that there are sev-
eral similarities between EoE and IBD [30]. The core team consists 
of a study manager (C.S.), a questionnaire designer (E.S.), a data 
manager (D.G.), a biostatistician (J.-B.R.), a study center supervi-
sor (V.P.), and the principal investigator (A.M.S.).
The SEECS project started in 2015 with the creation of ques-
tionnaires for screening, enrollment, and follow-up visits. Online 
supplementary Table 1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000486131) gives an overview of the 
questionnaires and the persons responsible for their completion. 
The questionnaires for physicians/study nurses were created in 
English, whereas the patient questionnaires were created in Ger-
man, French, and English.
In addition, documents for the institutional review boards 
(IRB) were written. Switzerland has 7 ethics committees which 
cover a total of 26 cantons (country districts). Figure 1 shows the 
location of the major centers of inclusion and their working areas. 
The SEECS project was submitted to the ethics committee of the 
canton of Vaud (CER-VD), which acts as the leading committee. 
After approval of the project by the CER-VD in 2015 (protocol No. 
148/15), the SEECS documents were sent to 5 other IRB (EKNZ, 
Bern, Geneva, EKOS, and Zurich), which granted approval in 
2015–2016. These 6 IRB cover the entire German- and French-
speaking parts of Switzerland. The documents have not yet been 
submitted to the IRB of the canton of Ticino for the inclusion of 
Italian-speaking patients. SIBDCS nurses at IBD centers also in-
clude EoE patients. Patient inclusion started in January 2016. Al-
though being a purely observational study, the SEECS was rated as 
category “B” by the CER-VD, which means that there is a minimal 
risk for potential harm due to acquisition of blood samples and 
esophageal biopsies for study purposes. As such, all included pa-
tients are covered by an insurance policy that has been issued by 
the Centre Hospitalier Universitaire Vaudois and which is valid for 
all participating patients irrespective of the location of inclusion.
Eligibility Criteria and Recruitment Process
The eligibility of adult patients (age ≥18 years) is assessed by 
use of the screening questionnaire. For inclusion, patients must 
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fulfil the following criteria according to the diagnostic guidelines: 
(1) symptoms of esophageal dysfunction and (2) a peak eosinophil 
count ≥15 per high-power field (400× magnification) despite 
treatment with PPI (single or double standard dose) for ≥8 weeks 
[5]. Patients with PPI-REE must fulfil the following criteria for in-
clusion: (1) symptoms of esophageal dysfunction; (2) clinical and 
histologic response upon 8-week treatment with PPI in single or 
double standard dose; and (3) no GERD [5]. Patients with EoE and 
concomitant GERD can be included if the diagnosis of EoE and 
GERD has been established based on accepted diagnostic criteria 
[5].
Patients are excluded in case of a permanent address outside 
Switzerland, refusal to sign the informed consent form, and/or 
conditions other than EoE or PPI-REE associated with esophageal 
eosinophilia, such as eosinophilic gastroenteritis, esophageal 
Crohn disease, connective tissue disorder, esophageal infection, 
etc. [5].
The SEECS datacenter hands out sets of paper-based question-
naires to gastroenterologists willing to recruit patients. The ques-
tionnaires are labeled with stickers that have a unique 9-digit iden-
tifier. The first 2 digits identify the recruiting center, whereas dig-
its 3–5 identify the recruiting physician, and digits 6–9 encode the 
patient. Patients first read the SEECS information sheet and pro-
vide their consent in case of willingness to participate. Additional 
consent is provided if the patient agrees with the performance of 
genetic studies on with his/her blood samples and esophageal bi-
opsies. The patients and the including gastroenterologist sign the 
informed consent sheet 3 times (1 sheet for the patient, 1 sheet for 
the datacenter, and 1 sheet for the patient file). The patients then 
sign a sheet that provides their contact information; in addition 
they choose whether they agree to be contacted for the administra-
tion of additional questionnaires during the year. All question-
naires are then labeled with the unique identifier tags. Thereby, 
patient recruitment is anonymized. The identification key is stored 
at the datacenter (IUMSP Lausanne).
Patients are typically included during a scheduled follow-up 
esophagogastroduodenoscopy. They complete the PRO question-
naire regarding symptoms and EoE-specific quality of life before 
the upper endoscopy. Symptoms are assessed using the validated 
EEsAI PRO questionnaire [22]. If willing, the patients also provide 
a blood sample for study purposes. They then undergo upper en-
doscopy with biopsy sampling for standard histology, which typi-
cally involves 3 biopsies from the distal and 3 biopsies from the 
proximal esophagus. These samples are fixed in formalin and sent 
to the local pathology institute in order to determine the severity 
of inflammatory and fibrotic features. In addition, 2 additional bi-
Fig. 1. Location of the major centers of inclusion and their working areas.
Cohort Profile: The Swiss Eosinophilic 
Esophagitis Cohort Study
167Inflamm Intest Dis 2017;2:163–170
DOI: 10.1159/000486131
opsies each from the distal and the proximal esophagus are taken 
for study purposes. These samples are stored in RNAlater (Invi-
trogen) to stabilize cellular RNA and DNA. The blood samples and 
esophageal biopsies are sent by mail to the biobank at the Institute 
of Pathology of the University of Bern. Besides biosamples of pa-
tients with EoE and PPI-REE, biosamples of patients with GERD 
and controls with a healthy esophagus are collected as well, and are 
stored in the central biobank. Inclusion of these control samples 
will facilitate translational studies, e.g., regarding esophageal bar-
rier dysfunctions, and thus elucidate disease pathogenesis.
The including gastroenterologist completes the physician 
questionnaires after endoscopy using standardized instruments to 
assess endoscopic and histologic activity [25, 26]. The patients are 
typically seen once a year for an endoscopic and histologic follow-
up examination, during which the follow-up questionnaires are 
administered. Table 1 provides an overview of the variables col-
lected, as well as the frequency of data collection. The follow-up 
questionnaire can also be used for an unscheduled event such as a 
medical visit due to acute food bolus impaction that necessitates 
endoscopic removal.
Findings to Date
In January 2016, patient recruitment started in the 5 
university hospitals of Lausanne, Geneva, Basel, Bern, 
and Zurich, as well as in the hospitals of Lucerne, St. Gal-
len, and the Swiss EoE Clinic in Olten, Switzerland. The 
project aims for a yearly recruitment rate of 70 new pa-
tients with EoE or PPI-REE. Figure 2 shows the number 
of patients with EoE or PPI-REE recruited per month 
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Table 1. Variables captured by the SEECS questionnaires as well as the frequency of their completion
Measurements Questionnaire Frequency of data collection
physician patient screening sheet at inclusion at follow-up
Inclusion and exclusion criteria x x
Diagnosis x x x x
Clinical activity x x x x
Quality of life x x x
Endoscopic activity in EoE/PPI-REE x x x
Endoscopic activity in concomitant GERD x x x
Histologic activity in EoE/PPI-REE x x x
Blood eosinophilia x x x
Current therapy for EoE/PPI-REE x x x
Current therapy for other conditions1 x x x
Disease activity x x x
Management decision x x x
Past medical history x x x
Past therapy for EoE/PPI-REE x x x
Clinical activity assessed monthly x x
Adverse events related to EoE drugs x x
New medical examinations x x
Complications x x
SEECS, Swiss Eosinophilic Esophagitis Cohort Study; EoE, eosinophilic esophagitis; PPI-REE, proton pump inhibitor-responsive 
esophageal eosinophilia; GERD, gastroesophageal reflux disease. 1 Includes therapies for concomitant asthma, rhinoconjunctivitis, ec-
zema, or GERD.
Fig. 2. Cumulative numbers of patients with eosinophilic esopha-
gitis (EoE) and proton pump inhibitor-responsive esophageal eo-
sinophilia (PPI-REE) included between January 2016 and July 
2017. SEECS, Swiss Eosinophilic Esophagitis Cohort Study.
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since January 2016. By the end of July 2017, a total of 111 
patients with EoE and 10 patients with PPI-REE were re-
cruited. A total of 5 EoE patients (5/126; 4%) declared 
their unwillingness to participate. Thus, the participation 
rate of patients with EoE and PPI-REE was 96%. In addi-
tion, biopsies and blood samples from 11 patients with 
GERD and 20 controls with a healthy esophagus were col-
lected. The baseline characteristics of the patients and the 
numbers of biosamples as of July 2017 are shown in Table 
2. The mean age of the patients with EoE was 39.6 ± 12.9 
years, and that of the PPI-REE patients was 44.6 ± 15.6 
years. A male predominance was found for both the pa-
tients with EoE (77.5%) and those with PPI-REE (70%). 
Concomitant allergic disorders were found in 79.3% of 
the patients with EoE and 90% of the patients with PPI-
REE. Nearly all patients (99.1%) with EoE had a distinc-
tive therapy at inclusion, with swallowed topical steroids 
(82.9%) being the most frequently applied drug, followed 
by PPI (36%). Elimination diets were practiced by 15.3% 
of the EoE patients at inclusion. All patients with PPI-
REE were on treatment at inclusion, with PPI being pre-
scribed to 90% of these patients.
Strengths and Limitations
The SEECS has several strengths and also some limita-
tions. To the best of our knowledge, it provides the first 
national cohort of patients with EoE and PPI-REE. Pa-
tients are included based on strict diagnostic criteria [4]. 
Assessment of clinical and biologic disease activity is 
based on validated instruments designed specifically for 
EoE and PPI-REE [22, 25, 26]. The cross-sectional capture 
of data regarding clinical activity, EoE-specific quality of 
life, and endoscopic and histologic activity will help to 
clarify the controversially discussed relationship between 
Table 2. Baseline characteristics of the included subjects as well as numbers of biosamples as of July 2017
EoE PPI-REE GERD Healthy
controls
Subjects 111 10 11 20
Male/female 86/25 7/3 4/7 7/13
Mean age at inclusion ± SD, years 39.6±12.9 44.6±15.6 59.9±12.7 51.1±15.2
Mean diagnostic delay ± SD, years 4.3±3.8 2.6±3.0 – –
Concomitant GERD 18 (16.2%) – – –
Concomitant allergies
None 23 (20.7%) 1 (10%) – –
Overall 82 (73.9%) 7 (70%) – –
Rhinoconjunctivitis 57 (51.4%) 6 (60%) – –
Asthma 35 (31.5%) 4 (40%) – –
Neurodermatitis 11 (9.9%) 3 (30%) – –
Food allergies 39 (35.1%) 5 (50%) – –
Missing information 6 (5.4%) 2 (20%) – –
Current therapy
None 1 (0.9%) 0 10 –
Any 107 (96.4%) 10 (100%) 0 –
PPI 40 (36.0%) 9 (90%) 0 –
Swallowed topical corticosteroids 92 (82.9%) 0 0 –
Elimination diet 17 (15.3%) 2 (20%) 0 –
Esophageal dilation 22 (19.8%) 2 (20%) 0 –
Missing information 3 (2.7%) 0 1 (9.1%) –
Subjects providing esophageal biopsies1 147 12 15 19
Subjects providing blood samples
EDTA 148 10 16 16
Serum 77 5 8 8
EoE, eosinophilic esophagitis; PPI-REE, proton pump inhibitor-responsive esophageal eosinophilia; GERD, 
gastroesophageal reflux disease. 1 Regarding biosamples: 1 patient could be counted several times if >1 endos-
copy was performed.
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PRO and biologic activity [31]. Follow-up information is 
typically captured once a year. Biosamples are collected 
not only from patients with EoE and PPI-REE, but also 
from patients with GERD and from controls with a healthy 
esophagus, which is critical for translational projects.
As a first limitation, the SEECS is not population 
based. In addition, we currently abstain from the inclu-
sion of pediatric patients with EoE and PPI-REE. A vali-
dated PRO instrument in German and French for pediat-
ric EoE patients is currently lacking, which hampers the 
inclusion of pediatric patients. The EEsAI study group is 
currently developing such an instrument. Hence, the in-
clusion of pediatric EoE patients has been designated for 
a later stage. Second, for the time being, we have not cre-
ated any questionnaires for the Italian-speaking canton of 
Ticino in southern Switzerland. As of the end of 2016, the 
canton of Ticino had 354,357 inhabitants, which corre-
sponds to 4.43% of the entire Swiss population (currently 
about 8 million people). The inclusion of Italian-speaking 
patients is planned in a later step.
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